AOD-9604

AOD-9604 does not have an approved clinical dosing label for research-use peptide products. Published human studies have primarily evaluated oral AOD-9604 rather than the lyophilized vial format used in research markets. In one phase IIb obesity study, oral AOD-9604 was studied across 1 mg, 5 mg, 10 mg, 20 mg, and 30 mg daily dose groups over 12 weeks. Another phase IIb study evaluated lower oral tablet ranges of 0.25 mg, 0.5 mg, and 1 mg over 24 weeks. These clinical-study amounts should be treated as research-reference context only and should not be presented as personal dosing instructions.

In researcher-reported exploratory settings using lyophilized AOD-9604, commonly discussed ranges often fall around 250-500 mcg per day, with some research discussions describing daily or five-day-per-week schedules over approximately 8-12 week observation windows. These ranges are anecdotal research-context references, not validated recommendations. Protocol design depends on the study model, concentration, route, tissue target, metabolic endpoint, and safety controls being used.

For storage and handling, AOD-9604 should follow standard peptide-integrity practices. Store unopened lyophilized vials refrigerated when possible and protected from direct light, heat, and repeated temperature changes. Once reconstituted, keep refrigerated and avoid unnecessary warming, freezing, or repeated agitation. If mixing is needed after adding diluent, gently swirl the vial rather than shaking it. Aggressive shaking can create foaming and may reduce peptide integrity over time.